🎉We are thrilled to celebrate another collaboration between our esteemed members, Serum Institute of India Pvt. Ltd. (SII) and Panacea Biotec, marking significant strides in vaccine development.
The upcoming commencement of the third phase of human trials for a dengue vaccine in April 2024 showcases their dedication to advancing healthcare. Should these trials prove successful, the potential for vaccine registration opens a new chapter in disease prevention.
Dr. Nivedita Gupta’s announcement at MICROCON-2023 about this pivotal phase in dengue vaccine implementation highlights the remarkable possibilities on the horizon.
This partnership reflects our shared commitment to fostering groundbreaking advancements in vaccine research and underscores the collective efforts of our members toward a healthier, more resilient future. Stay tuned for further updates on this promising development!
See the full article HERE
